Business Wire

RAYSUT-CEMENT-COMPANY

Share
Raysut Cement Gets CE, NF Certifications for Conforming to European Standards; Gears up to Export to EU Countries

In a significant endorsement that will support exports to European Union (EU) markets, Oman’s largest cement manufacturer, Raysut Cement Company (RCC), has received CE and NF certifications, two stringent global quality norms validating RCC’s adherence to EU standards in cement production.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210517005501/en/

The Muscat Stock Market (MSM)-listed RCC said the certifications come at a time when it is expanding exports to newer global markets. Currently, 50 per cent of the company’s output is exported to East Africa, India, Maldives, South Africa, and Indian Ocean islands.

“We consider CE and NF certifications a testimony to our commitment to constantly improve product quality and processes in line with rigorous global safety, quality and environmental regulations,” said Group CEO, Joey Ghose.

The CE (Conformité Européenne) mark, formerly EC mark, is mandatory for selling certain products in the European Economic Area (EEA) since 1985. The NF Mark from AFNOR certification entity is a French compliance norm that ensures product safety, quality, usage ability and performance.

“The certifications fit into our export strategy for newer geographies as the CE Mark that endorses compliance with EU’s health, safety and green regulations allows us to market our products in Iceland, Liechtenstein and Norway,” said Mr. Ghose.

Winning the certifications also coincided with RCC clinching a new export order from the Reunion Islands in the western Indian Ocean, and an annual contract has already been signed with Enterprise Audemard Group of the French island to ship 8,000 MT cement every month. The first shipment has been received by the party. RCC is also looking at setting up a grinding unit in Madagascar to leverage the 7-8 per cent Y-o-Y growth in that country’s market.

RCC has a current output of 6 million metric tonnes of cement, slated to increase to 10 million by 2022, and later to 22 million tonnes. Mr. Ghose said the COVID-19 pandemic has thrown a major challenge to the business, but RCC was facing it successfully with no change in leadership or vision.

Recently, RCC had won certifications from other parts of the world, boosting its export scope. These are from BIS (Bureau of Indian Standards), enabling it to stabilize its presence in India, and from SABPS (South African All Brothers Products and Systems) to help RCC leverage the South African market.

Mr. Salim bin Ahmed bin Alawi Al Ibrahim, Acting Deputy Group CEO of RCC said: “The cement now produced at RCC’s Salalah plant has accomplished the strictest environmental criterion of Hexavalent Chromium (Cr6+) content of less than two parts per million. The NF certification also opens up new market opportunities and we are now introducing a superior quality cement brand to the French colonies in the Indian Ocean Reunion Islands.”

Last year RCC won the ‘CEO of the Year’ honour for its Group CEO Mr. Joey Ghose, at both the Oman Best Employer Awards and GCC Best Employer Awards from Employer Branding Institute, which reinforced the company’s excellence across leadership, health and safety, technology, training and talent management.

“We regularly train our employees through on-the-job and by sending them overseas to upgrade their skills. This training helps us strictly implement quality, environmental and safety norms at our production facilities to improve our products in line with global demand,” added Mr. Al Ibrahim.

*Source: AETOSWire

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in

Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration

Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release

Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo

Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release

First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release

Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye